SLRX vs. MDVL, SNOA, PHIO, GRAY, SHPH, ABVC, ATHE, CANF, EFTR, and MTEM
Should you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include MedAvail (MDVL), Sonoma Pharmaceuticals (SNOA), Phio Pharmaceuticals (PHIO), Graybug Vision (GRAY), Shuttle Pharmaceuticals (SHPH), ABVC BioPharma (ABVC), Alterity Therapeutics (ATHE), Can-Fite BioPharma (CANF), eFFECTOR Therapeutics (EFTR), and Molecular Templates (MTEM). These companies are all part of the "medical" sector.
Salarius Pharmaceuticals (NASDAQ:SLRX) and MedAvail (NASDAQ:MDVL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations and profitability.
Salarius Pharmaceuticals has a net margin of 0.00% compared to MedAvail's net margin of -192.97%. Salarius Pharmaceuticals' return on equity of -152.20% beat MedAvail's return on equity.
In the previous week, Salarius Pharmaceuticals had 2 more articles in the media than MedAvail. MarketBeat recorded 2 mentions for Salarius Pharmaceuticals and 0 mentions for MedAvail. Salarius Pharmaceuticals' average media sentiment score of 1.43 beat MedAvail's score of 0.00 indicating that Salarius Pharmaceuticals is being referred to more favorably in the media.
Salarius Pharmaceuticals has higher earnings, but lower revenue than MedAvail. Salarius Pharmaceuticals is trading at a lower price-to-earnings ratio than MedAvail, indicating that it is currently the more affordable of the two stocks.
11.9% of Salarius Pharmaceuticals shares are owned by institutional investors. 5.5% of Salarius Pharmaceuticals shares are owned by insiders. Comparatively, 1.5% of MedAvail shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Salarius Pharmaceuticals has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, MedAvail has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.
Salarius Pharmaceuticals received 18 more outperform votes than MedAvail when rated by MarketBeat users. Likewise, 54.17% of users gave Salarius Pharmaceuticals an outperform vote while only 42.11% of users gave MedAvail an outperform vote.
Summary
Salarius Pharmaceuticals beats MedAvail on 11 of the 14 factors compared between the two stocks.
Get Salarius Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Salarius Pharmaceuticals Competitors List
Related Companies and Tools
